PXS
From IntFX
[edit] Profile
[edit] Company Overview
Pharmaxis Ltd (Pharmaxis) is an Australian specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and inflammatory/autoimmune diseases. The Company has developed Aridol, as a tool for the diagnosis of asthma and management of asthma and chronic obstructive pulmonary disease (COPD). The Aridol test mimics the bronchoconstriction that occurs in inflamed airways during asthma episodes and may be used to assist with the identification of people who have airway hyperresponsiveness, an indication of untreated or poorly controlled asthma. Aridol may also be used to determine the appropriate doses of anti-inflammatory medicine, such as inhaled corticosteroids. Pharmaxis received marketing approval in Australia in March 2006, and commenced commercial supply of Aridol in Australia in June 2006. In October 2006, the Company obtained marketing approval in Sweden.
[edit] News/Discussion & Announcements
|
|
|
|
[edit] Upcoming Events
